tiprankstipranks

Acrivon Therapeutics price target lowered to $9 from $10 at Oppenheimer

Oppenheimer lowered the firm’s price target on Acrivon Therapeutics (ACRV) to $9 from $10 and keeps an Outperform rating on the shares. The firm is adjusting its model after the company’s Q1 results and updates on its cash and share position, the analyst tells investors in a research note.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

1